Neurodevelopmental Outcome After Fetal Neonatal AlloImmune Thrombocytopenia

计划入组 78 人 · 首次发布于 2020 年 8 月 27 日

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

计划入组 39 人 · 首次发布于 2024 年 6 月 10 日

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

计划入组 50 人 · 首次发布于 2024 年 8 月 1 日

apoptosis inhibitors (thrombocytopenia)

Foreskin keratinocyte (neonatal)(Gintuit)

Foreskin fibroblast (neonatal)(Gintuit)

HOSPITAL MATERNO NEONATAL

Argentina

FETAL MEDICINE FOUNDATION

United States

Fetal Life LLC

United States

Rallybio's RLYB212 Phase 2 Trial for FNAIT Prevention Set to Initiate Screening

Nipocalimab Granted FDA Breakthrough Therapy Designation for Sjögren’s Disease

Johnson & Johnson Halts Rheumatoid Arthritis Trial for Nipocalimab, Refocuses on Rare Disease Markets